George Cholankeril
Appearances
- DateMay 8, 2023BACKGROUND AND AIMS: Screening tools are needed for early detection of NAFLD-fibrosis. We aimed to identify risk factors for NAFLD-fibrosis in the multiethnic population of the U.S. and thus accelerate development of equitable screening tools…
Presenter
Michael E. DeBakey VAMCSpeakers
Baylor College of Medicine - DateMay 6, 2023BACKGROUND The prevalence of chronic liver disease is increasing but it remains underdiagnosed, with frequent late presentation. Development in early adulthood is likely to associate with higher lifetime cirrhosis risk but early identification of asymptomatic patients can prove challenging…
Presenter
Speakers
University of Texas Southwestern Medical Center - DateMay 19, 2024BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease without medical cure, that confers a significantly elevated risk of malignancy, acute cholangitis and cirrhosis. Approximately 2-7% of patients with inflammatory bowel disease (IBD) will develop PSC…
Presenter
Stanford University - DateMay 18, 2024BACKGROUND: Patients with MASLD and diabetes have an increased risk of cirrhosis and hepatocellular cancer (HCC). Recent studies show that glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, are effective in improving liver inflammation in MASLD…
Presenter
Michael E. DeBakey VAMCSpeakers
The Perelman School of Medicine at the University of PennsylvaniaBaylor College of Medicine - DateMay 21, 2024BACKGROUND: Current understanding of the rates and trajectories of progression to cirrhosis complications is derived from outdated data. We examined the progression patterns of cirrhosis and their implications, focusing on the different outcomes of prolonged illness _vs_…
Speakers
Baylor College of MedicinePresenter
Michael E. DeBakey VAMC